Validation of the SLE-DAS responder index as an accurate and feasible endpoint for SLE clinical trials: A post-hoc study in the phase 2 and 3 ANIFROLUMAB clinical trials      (Journal Article)

<Overall Information> Journal Name: Annals of the Rheumatic Diseases Doi: 10.1136/annrheumdis-2024-eular.4639 Volume: 83, Supplement 1 Pages: 1004-1005 Revision: No